EUVIMEDEUVIMED entdecken
Crossref

Trends in Mortality for Anaplastic Thyroid Cancer: Have We Made Progress?

Bosung N Titanji, Michelle Earley, Electron Kebebew

Journal of Surgical Research · 2024

DOI: 10.1016/j.jss.2024.07.075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Research, 2024. Verfasst von Bosung N Titanji und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Stanford University, Palo Alto, California; Meharry Medical College School of Medicine, Nashville, Tennessee. Electronic addre…. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, SEER Program. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Anaplastic thyroid cancer (ATC) has one of the highest mortality rates of all human malignancies, accounting for two-thirds of all thyroid cancer deaths. Despite multimodal treatment, ATC still has a reported median survival period of 6 mo. Recent single-center studies have reported improved survival with the approval of new treatments for ATC. In this study, we sought to investigate whether the approval of new treatments and use of multimodal treatments was associated with reduced risk of mortality over time nationally. METHODS: Eight hundred and seventy four patients in the National Cancer Institute's Surveillance, Epidemiology, and End Results database that were diagnosed with ATC from 1990 to 2020 were included in this study. Cox proportional hazards models were used to assess the change in 2-y survival over time and to identify characteristics associated with survival. Overall survival (OS) and cancer specific survival (CSS) were both evaluated. RESULTS: The OS within 2 y of diagnosis was 14% and the CSS was 19%. For every 3-y increase in diagnosis year from 1990 to 2020, there was no significant change in the CSS (adjusted hazard ratio [95% confidence interval]: 0.98 [0.94, 1.01]). Patients who received treatment (surgery, chemotherapy, and/or radiation) had an increased CSS (adjusted hazard ratio [95% confidence interval]: 0.42 [0.32, 0.55]). CONCLUSIONS: We observed no significant change in OS or CSS after adjusting for confounders by year of diagnosis. Though receiving treatment was associated with increased CSS, more effective treatments are needed in the future to increase survival time in patients with ATC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsSEER ProgramHumansMaleFemaleMiddle AgedAgedUnited StatesAged, 80 and overAdultCombined Modality TherapyRetrospective StudiesThyroidectomy

Stichwörter der Autor:innen

Anaplastic thyroidBRAFCancerSurvivalTreatmentUndifferentiated thyroid cancer

Autor:innen und Institutionen

  • Department of Surgery, Stanford University, Palo Alto, California; Meharry Medical College School of Medicine, Nashville, Tennessee. Electronic address: btitanji1@gmail.com.
  • Department of Surgery, Stanford University, Palo Alto, California.

Zitieren

APA

Titanji, B. N., Earley, M., & Kebebew, E. (2024). Trends in Mortality for Anaplastic Thyroid Cancer: Have We Made Progress?. Journal of Surgical Research. https://doi.org/10.1016/j.jss.2024.07.075

Vancouver

Titanji BN, Earley M, Kebebew E. Trends in Mortality for Anaplastic Thyroid Cancer: Have We Made Progress?. Journal of Surgical Research. 2024. doi:10.1016/j.jss.2024.07.075

BibTeX
@article{Titanji2024,
  author = {Titanji, Bosung N and Earley, Michelle and Kebebew, Electron},
  title = {Trends in Mortality for Anaplastic Thyroid Cancer: Have We Made Progress?},
  journal = {Journal of Surgical Research},
  year = {2024},
  doi = {10.1016/j.jss.2024.07.075}
}
Kostenlos starten →